Acadian Asset Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,064
| Closed | -$5K | – | 1944 |
|
|
2024
Q1 | $5K | Sell |
1,064
-4,739
| -82% | -$22.3K | ﹤0.01% | 1528 |
|
|
2023
Q4 | $38K | Sell |
5,803
-2,131
| -27% | -$14K | ﹤0.01% | 1493 |
|
|
2023
Q3 | $71K | Buy |
7,934
+1,064
| +15% | +$9.52K | ﹤0.01% | 1377 |
|
|
2023
Q2 | $145K | Sell |
6,870
-2,546
| -27% | -$53.7K | ﹤0.01% | 1337 |
|
|
2023
Q1 | $253K | Sell |
9,416
-6,934
| -42% | -$186K | ﹤0.01% | 1208 |
|
|
2022
Q4 | $578K | Buy |
+16,350
| New | +$578K | ﹤0.01% | 992 |
|
|
2021
Q3 | – | Sell |
-445
| Closed | -$114K | – | 2085 |
|
|
2021
Q2 | $114K | Buy |
+445
| New | +$114K | ﹤0.01% | 1604 |
|
|
2020
Q1 | – | Sell |
-97
| Closed | -$43K | – | 1973 |
|
|
2019
Q4 | $43K | Buy |
+97
| New | +$43K | ﹤0.01% | 1621 |
|
|
2019
Q3 | – | Sell |
-387
| Closed | -$123K | – | 2053 |
|
|
2019
Q2 | $123K | Sell |
387
-141
| -27% | -$44.8K | ﹤0.01% | 1339 |
|
|
2019
Q1 | $221K | Sell |
528
-1,227
| -70% | -$514K | ﹤0.01% | 1332 |
|
|
2018
Q4 | $535K | Sell |
1,755
-1,159
| -40% | -$353K | ﹤0.01% | 883 |
|
|
2018
Q3 | $1.05M | Buy |
2,914
+1,038
| +55% | +$374K | ﹤0.01% | 716 |
|
|
2018
Q2 | $687K | Buy |
1,876
+1,184
| +171% | +$434K | ﹤0.01% | 816 |
|
|
2018
Q1 | $204K | Buy |
+692
| New | +$204K | ﹤0.01% | 1055 |
|